Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10988226 | 0.86 | TSPO (0.47) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL8404094 | 0.85 | TSPO (0.49) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL13607936 | 0.82 | TSPO (0.79) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL2139928 | 0.82 | TSPO (0.59) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL10985563 | 0.78 | KDM4E (0.48) | MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL8471215 | 0.77 | TSPO (0.59) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL10990750 | 0.75 | GRM2 (0.48) | MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL28815511 | 0.74 | ALDH1A1 (0.50) | ALDH1A1NPSR1 | |
| SCHEMBL8472399 | 0.74 | TSPO (0.56) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL10985666 | 0.73 | MEN1 (0.49) | TSPOMEN1KMT2ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424532-B1 | COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8716302-B2 | Compounds for inducing cellular apoptosis | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716302-B2 | Compounds for inducing cellular apoptosis | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-05-06 | — | — | US | disclosed |
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | QUEEN MARY AND WESTFIELD COLLEGE (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | QUEEN MARY AND WESTFIELD COLLEGE (GB) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | BAD, BAX, CASP3 | TSPO 1625/4885MEN1 4188/4885KMT2A 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.